UniProt P29317 · PDB · AlphaFold · Substrate: pEY · Clone: cytoplasmichigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 99.7% | 0.3% | 87.22 | 0.555 |
| 2 | Repotrectinib | 99.6% | 0.4% | 84.21 | 0.608 |
| 3 | Dasatinib | 99.4% | 0.6% | 87.97 | 0.699 |
| 4 | Ponatinib | 98.6% | 1.4% | 78.23 | 0.534 |
| 5 | Nilotinib | 97.6% | 2.4% | 96.49 | 0.765 |
| 6 | Crizotinib | 96.0% | 4.0% | 91.39 | 0.581 |
| 7 | Ripretinib | 95.2% | 4.8% | 92.95 | 0.674 |
| 8 | Tivozanib | 92.6% | 7.4% | 92.42 | 0.673 |
| 9 | Fostamatinib | 87.9% | 12.1% | 96.74 | 0.613 |
| 10 | Cabozantinib | 87.0% | 13.0% | 92.73 | 0.751 |
| 11 | Vandetanib | 86.9% | 13.1% | 95.74 | 0.723 |
| 12 | Erdafitinib | 76.4% | 23.6% | 95.71 | 0.737 |
| 13 | Canertinib | 72.6% | 27.4% | 96.49 | 0.671 |
| 14 | Gilteritinib | 70.4% | 29.6% | 88.97 | 0.506 |
| 15 | Apatinib | 60.4% | 39.6% | 97.73 | 0.704 |
| 16 | Umbralisib | 51.0% | 49.0% | 98.74 | 0.670 |
| 17 | Selpercatinib | 45.3% | 54.7% | 96.72 | 0.635 |
| 18 | Upadacitinib | 42.4% | 57.6% | 97.98 | 0.663 |
| 19 | Nintedanib | 41.1% | 58.9% | 90.23 | 0.608 |
| 20 | Alectinib | 36.4% | 63.6% | 95.49 | 0.651 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.40
- Epithelial log2(TPM+1): 4.18
- Fold change: 1.22
- Status: Upregulated
High-confidence drugs
- Nilotinib — inh 97.6% · KISS 48.70
- Dasatinib — inh 99.4% · KISS 41.66
- Ripretinib — inh 95.2% · KISS 36.75
Selectivity landscape vs inhibition on EPHA2
Each point is one of the 92 approved drugs; color = inhibition % on EPHA2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…